Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Healthy
Interventions: ethinyl estradiol, norethindrone, VI-0521; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 64 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cystic Fibrosis
Interventions: Exercise Intervention; Behavioral
Lead sponsor: Wuerzburg University Hospital; Other
Eligibility: 12 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Emotion Management Skills, Lifestyle, Healthy, Lifestyle Intervention, Recovery, Exercise and Recovery, Exercise Training, Anxiety and Mood Disorders, Sleep, Motivation, Comfort, Pain Management, Rehabilitation, Creativity and Mindfulness
Interventions: soundBrilliance software application - Emotional Health; Device
Lead sponsor: soundBrilliance LLC; Industry
Eligibility: 13 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Fort Collins, Colorado • Omaha, Nebraska • Reno, Nevada

Conditions: Orthopoxviral Disease
Interventions: ST-246 400 mg, ST-246 600 mg, Placebo; Drug
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Santa Ana, California • Orlando, Florida • Honolulu, Hawaii

Conditions: Brain and Central Nervous System Tumors
Interventions: surgical procedure, brachytherapy, intraoperative radiation therapy, iodine I 125; Procedure · Radiation
Lead sponsor: New Approaches to Brain Tumor Therapy Consortium; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Knee Osteoarthritis, Osteo Arthritis Knee
Interventions: Microfragmented Adipose Tissue derived using the Lipogems® System, Saline Injection; Device · Drug
Lead sponsor: Lipogems International spa; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Phoenix, Arizona • Encinitas, California • La Mesa, California + 13 more

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Barrett's Esophagus, High Grade Dysplasia, Low Grade Dysplasia
Interventions: CryoSpray Ablation System (510(k) NO: K070893); Device
Lead sponsor: CSA Medical, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 16
States / cities: Orange, California • Norwalk, Connecticut • Tampa, Florida + 12 more

Conditions: Type 2 Diabetes Mellitus
Interventions: dutogliptin, sitagliptin; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more

Conditions: Friedreich Ataxia, Cardiomyopathies, Central Nervous System Diseases, Neuromuscular Diseases, Mitochondrial Diseases, Mitochondrial Dysfunction, Genetic Disease
Interventions: ATI-105, Placebo; Drug
Lead sponsor: Adjuvia Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more

Conditions: Multiple Sclerosis
Interventions: Tolebrutinib, gemfibrozil, rifampicin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Keratoconus
Interventions: Riboflavin Ophthalmic Solutions, UV-A Irradiation System; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 13 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Westerville, Ohio

Conditions: Deep Brain Stimulation
Interventions: SIS System; Device
Lead sponsor: Surgical Information Sciences Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism, Multiple System Atrophy, Brain Tumor Adult, Spinal Cord Injuries, Locked-in Syndrome
Interventions: BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying, BCI-FIT language modeling; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Asthma
Interventions: Placebo, RO4989991; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: South Miami, Florida • Normal, Illinois • Raleigh, North Carolina + 1 more

Conditions: Rotator Cuff
Interventions: HEALICOIL Knotless PEEK, HEALICOIL Knotless REGENESORB; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Redwood City, California • Colorado Springs, Colorado • Denver, Colorado + 2 more

Conditions: Heart Failure NYHA Class III
Interventions: Cordella™ Heart Failure System; Device
Lead sponsor: Endotronix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Lebanon, New Hampshire + 1 more

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Chronic Heart Failure With Preserved Ejection Fraction
Interventions: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 29
States / cities: Beverly Hills, California • Carmichael, California • West Hills, California + 26 more

Conditions: Metastatic Melanoma
Interventions: TLPLDC Vaccine; Drug
Lead sponsor: Elios Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 4 more

Conditions: Rett Syndrome, Prader-Willi Syndrome, Angelman Syndrome, Sleep Problems
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Enrollment: 804 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • Irvine, California • San Diego, California + 6 more

Search by objective public record fields.

Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

Effects of a Partially Supervised Conditioning Program in CF

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

The Impact of Enhanced Music & Natural Visuals on Emotional Health

Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246

Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors

BAX 855 PK-guided Dosing

Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

SIS Evaluation of the MRI Defined Subthalamic Nucleus*

Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit

A Study of RO4989991 in Patients With Allergic Rhinitis

Safety of Treatment of Shoulder Repair

PRODIGY Registry in NYHA Class III Heart Failure Patients

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW